Swiftscale Biologics

What Swiftscale Biologics does

Swiftscale Biologics is a private biotechnology company founded in 2019 and based in South San Francisco, California. The firm employs 11-50 people and is developing a cell-free protein synthesis (CFPS) platform intended to enable the next generation of protein therapeutics. The company is led by co-founders David M. (CEO), Matthew Delisa (Chief Scientific Officer), and Michael Jewett (Chief Technology Officer), with a leadership team that combines operational and deep technical expertise in cell-free biology.

The company's core technology is cell-free protein synthesis, an alternative to traditional cell-based protein production that uses cellular machinery outside of living cells to manufacture proteins. This modality is positioned to address speed, complexity, and manufacturability limitations in producing protein-based therapeutics, though no specific product candidates, therapeutic indications, or named development partners are disclosed in the source material.

Swiftscale has raised a cumulative $15 million across two funding rounds in 2019 and 2020, both led by 8VC. The most recent disclosed event is a $11M round in June 2020, nearly 3x the size of the 2019 seed. There is no disclosed revenue, customer base, commercial partnership, or pipeline milestone in the source data, suggesting the company remains in an early, pre-commercial R&D stage as of the latest available information.

Name

Swiftscale Biologics

Website

https://swiftscalebio.com

Company type

Private

Founded year

2019

Headcount range

11–50 employees

Short description

Swiftscale Biologics is a private South San Francisco biotech founded in 2019 that builds a cell-free protein synthesis platform to manufacture next-generation protein therapeutics. The 11-50 person company is founder-led and has raised $15M from 8VC.

Ownership category

akta.pro rank

Product category

Biologics Manufacturing & Cell-free Protein Synthesis

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC)

akta.pro secondary industries

Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds) (HLAAAAAJ), Therapeutic Peptides & Protein/Peptide Biologics (HLAAAAAH)

Keywords

• Cell-free protein synthesis
• Protein therapeutics
• Biologics manufacturing
• Synthetic biology platform
• Therapeutic protein engineering

Headquarters

HQ city

South San Francisco

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Core offering

Swiftscale Biologics uses cell-free protein synthesis to enable the next generation of protein therapeutics. The company leverages this approach to produce and engineer therapeutic proteins without relying on living cells, accelerating biologics development for pharmaceutical and biotechnology customers.

Differentiator

Problem solved

Functional benefit

Products and services

• Cell-free protein synthesis platform Proprietary cell-free protein synthesis technology used to design, produce, and engineer protein therapeutics without living cells, offered to pharmaceutical and biotechnology customers developing biologics.

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves3 records

Expansion highlights3 records

Direct peers

• Sutro Biopharma: Sutro Biopharma is a clinical-stage biotech that pioneered cell-free protein synthesis (XpressCF) for the manufacture of cytokines, antibody-drug conjugates, and other complex therapeutics. It is the most direct competitor to Swiftscale in applying cell-free systems to protein therapeutic development.
• Codexis: Codexis engineers proteins (notably enzymes) using directed evolution and proprietary platforms for therapeutic and industrial applications. It is highly comparable to Swiftscale's protein-engineering focus, though its primary commercial engine today is in biocatalysis and pharma manufacturing services rather than therapeutics.
• Tierra Biosciences: Tierra Biosciences operates a cell-free protein synthesis platform that enables on-demand expression of proteins for research and therapeutic discovery. It shares Swiftscale's core technology foundation and customer base in protein engineering and drug discovery.

Emerging players

• Generate Biomedicines: Generate Biomedicines is a generative-AI platform for designing novel protein therapeutics across modalities. It is an emerging player in the protein therapeutics space where Swiftscale's cell-free synthesis could serve as a rapid prototyping and validation engine.
• Cradle Bio: Cradle uses machine learning to engineer proteins and enzymes for biotech applications. It is comparable to Swiftscale as a fellow protein-engineering platform startup, although its end markets skew toward industrial biotech.
• Amunix Pharmaceuticals: Amunix develops engineered protein therapeutics with masking and half-life extension technologies. It is comparable to Swiftscale in the engineered-protein therapeutic category, although Amunix uses more traditional expression systems.

Broad incumbents

• Arcturus Therapeutics: Arcturus is a clinical-stage biotech developing RNA therapeutics with proprietary manufacturing and delivery technologies. It is a broader incumbent in the nucleic acid/protein therapeutics space where Swiftscale's cell-free platform could enable alternative modalities.
• Ginkgo Bioworks: Ginkgo Bioworks operates a broad synthetic biology and cell engineering platform serving multiple end markets including therapeutics. It is a broad incumbent comparable to Swiftscale in leveraging biological engineering for protein-related applications, though at much larger scale.

Market position

Strengths3 records

Weaknesses4 records

Competitive moat2 records

Key risks4 records

Key highlights4 records

Customer concentration

• LinkedInlinkedin.com/company/swiftscale-biologics

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Swiftscale Biologics